ノースカロライナにおける重症筋無力症の臨床試験
ノースカロライナ内の拠点で、重症筋無力症に関する14件の研究が参加者を募集しています。
ノースカロライナ内の都市
公式研究テキスト（英語）
Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
- Velocity Clinical Research, Inc., Raleigh
- Atrium Health Wake Forest Baptist, Winston-Salem
被験者募集中第3相
18歳〜74歳 · 全性別 · 2026/09/25更新 · NCT07217587A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
- Cinical Study Site, Fayetteville
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/09/25更新 · NCT07647510ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
- University of North Carolina at Chapel Hill-170 Manning Dr., Chapel Hill
- Duke Early Phase Clinical Research Unit - PPDS, Durham
被験者募集中観察研究
18歳以上 · 全性別 · 2026/09/24更新 · NCT07294170ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
- University of North Caroline at Chapel Hill-170 Manning Dr, Chapel Hill
- Duke Early Phase Clinical Research Unit - PPDS, Durham
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/24更新 · NCT07284420A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
- TG Therapeutics Investigational Trial Site, New Bern
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/22更新 · NCT07673744Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
- UNC Hospitals - PARENT, Chapel Hill
- Atrium Health Wake Forest Baptist, Winston-Salem
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/16更新 · NCT06463587Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
- The University of North Carolina at Chapel Hill, Chapel Hill
被験者募集中第2相
18歳以上 · 全性別 · 2026/08/21更新 · NCT06414954Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
- Site Number - 1020, Chapel Hill
- Site Number - 1013, Durham
- Site Number - 1044, Raleigh
被験者募集中第3相
18歳〜80歳 · 全性別 · 2026/07/30更新 · NCT07039916A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
- Duke University School of Medicine, Durham
被験者募集中第3相
18歳以上 · 全性別 · 2026/07/27更新 · NCT04951622A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)
- University of North Carolina Hospitals - Neurology Clinic, Chapel Hill
被験者募集中第3相
18歳以上 · 全性別 · 2026/06/18更新 · NCT06456580A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab
- Research Site, Raleigh
被験者募集中第4相
18歳以上 · 全性別 · 2026/04/09更新 · NCT07221838Registry of Participants With Generalized Myasthenia Gravis Treated With Alexion C5 Inhibition Therapies (C5ITs)
- Clinical Trial Site, Chapel Hill
- Clinical Trial Site, Charlotte
- Clinical Trial Site, Durham
被験者募集中観察研究
18歳以上 · 全性別 · 2026/02/18更新 · NCT04202341Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis
- University of North Carolina at Chapel Hill, Chapel Hill
被験者募集中第2/3相
2歳〜18歳 · 全性別 · 2026/02/18更新 · NCT04833894The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis
- Duke University, Durham
被験者募集中健康なボランティア歓迎
18歳以上 · 全性別 · 2025/04/11更新 · NCT05564936ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。